Literature DB >> 10924999

The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors.

A Zurlo1, A Lomax, A Hoess, T Bortfeld, M Russo, G Goitein, V Valentini, L Marucci, R Capparella, A Loasses.   

Abstract

PURPOSE: The purpose of this study was to examine the potential benefit of proton therapy for abdominal tumors. Extensive comparative planning was conducted investigating the most up-to-date photon and proton irradiation technologies. METHODS AND MATERIALS: A number of rival plans were generated for four patients: two inoperable pancreatic tumors, one inoperable and one postoperative biliary duct tumor. The dose prescription goal for these large targets was 50 Gy, followed by a boost dose up to 20 Gy to a smaller planning target volume (PTV). Photon plans were developed using "forward" planning of coplanar and noncoplanar conformal fields and "inverse" planning of intensity-modulated (IM) fields. Proton planning was simulated as administered using the so called spot-scanning technique. Plans were evaluated on the basis of normal tissues' dose-volume constraints (Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1990;21:109-122) and coverage of treatment volumes with prescribed doses.
RESULTS: For all cases, none of the forward calculated photon plans was able to deliver 50 Gy to large PTVs at the same time respecting the dose-volume constraints on all critical organs. Nine evenly spaced IM fields achieved or nearly achieved all maximum dose constraints to critical structures for two out of three inoperable patients. IM plans also obtained good results for the postoperative patient, even though the dose to the liver was very close to the maximum allowed. In all cases, photon irradiation of large PTV1s to 50 Gy followed by a 20 Gy boost entailed a risk very close to or higher than 5% for serious complications to the kidneys, liver, or bowel. Simple arrangements of 2, 3, and 4 proton fields obtained better dose conformation to the target, allowing the delivery of planned doses including the boost to all patients, without excessive risk of morbidity. Dose homogeneity inside the targets was also superior with protons.
CONCLUSION: For the irradiation of large PTVs located in the abdominal cavity, where multiple, parallel structured organs surround the target volumes, proton therapy, delivered with a sophisticated isocentric technique, has the potential to achieve superior dose distributions compared with state-of-the-art photon irradiation techniques. IM photon plans obtain better results in the postoperative case, because the reduced volume lessens the effect of the unavoidable increase of integral dose to surrounding tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924999     DOI: 10.1016/s0360-3016(00)00522-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma.

Authors:  Phillip J Taddei; Rebecca M Howell; Sunil Krishnan; Sarah B Scarboro; Dragan Mirkovic; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

Review 2.  Proton beam therapy for gastrointestinal cancers: past, present, and future.

Authors:  Shahed N Badiyan; Christopher L Hallemeier; Steven H Lin; Matthew D Hall; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2018-10

Review 3.  Myths and realities of range uncertainty.

Authors:  Antony John Lomax
Journal:  Br J Radiol       Date:  2019-12-23       Impact factor: 3.039

4.  Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers.

Authors:  Richard Y Lee; Romaine C Nichols; Soon N Huh; Meng W Ho; Zuofeng Li; Robert Zaiden; Ziad T Awad; Bestoun Ahmed; Bradfors S Hoppe
Journal:  J Gastrointest Oncol       Date:  2013-12

Review 5.  Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review.

Authors:  Madelon Pijls-Johannesma; Janneke P C Grutters; Frank Verhaegen; Philippe Lambin; Dirk De Ruysscher
Journal:  Oncologist       Date:  2010-01-12

6.  Particle radiation therapy for gastrointestinal malignancies.

Authors:  Jeffrey J Meyer; Brian G Czito; Christopher G Willett
Journal:  Gastrointest Cancer Res       Date:  2007

Review 7.  Particle Radiation Therapy for Gastrointestinal Cancers.

Authors:  Makoto Shinoto; Daniel K Ebner; Shigeru Yamada
Journal:  Curr Oncol Rep       Date:  2016-03       Impact factor: 5.075

8.  Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer.

Authors:  Sarah Stefanowicz; Kristin Stützer; Sebastian Zschaeck; Annika Jakobi; Esther G C Troost
Journal:  Radiat Oncol       Date:  2018-11-22       Impact factor: 3.481

9.  Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical.

Authors:  Sarah Stefanowicz; Waldemar Wlodarczyk; Susanne Frosch; Sebastian Zschaeck; Esther G C Troost
Journal:  Clin Transl Radiat Oncol       Date:  2020-12-09

10.  Does vertebroplasty affect radiation dose distribution?: comparison of spatial dose distributions in a cement-injected vertebra as calculated by treatment planning system and actual spatial dose distribution.

Authors:  Atsushi Komemushi; Noboru Tanigawa; Shuji Kariya; Rie Yagi; Miyuki Nakatani; Satoshi Suzuki; Akira Sano; Koshi Ikeda; Keita Utsunomiya; Yoko Harima; Satoshi Sawada
Journal:  Radiol Res Pract       Date:  2012-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.